FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4225751411> ?p ?o ?g. }

• W4225751411 endingPage "6" @default.
• W4225751411 startingPage "5" @default.
• W4225751411 abstract "In the past 100 days, more than 3 billion doses of SARS-CoV-2 vaccines have been administered globally.1Mathieu E Ritchie H Ortiz-Ospina E et al.A global database of COVID-19 vaccinations.Nat Hum Behav. 2021; 5: 947-953Crossref PubMed Scopus (822) Google Scholar With 20 vaccines currently authorised in at least one country and 108 under clinical development as of July 20, 2021,2WHOCOVID-19 vaccine tracker and landscape.https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccinesDate accessed: July 21, 2021Google Scholar there is ongoing public concern regarding the possible adverse effects of SARS-CoV-2 immunisation. An adverse event reported in the product information of two vaccines developed with a novel mRNA technology is Bell's palsy, a form of acute facial nerve paralysis.3Cirillo N Reported orofacial adverse effects of COVID-19 vaccines: the knowns and the unknowns.J Oral Pathol Med. 2021; 50: 424-427Crossref PubMed Scopus (56) Google Scholar So far there has been no clear evidence of association between COVID-19 vaccination and facial paralysis. However, the findings from Eric Wan and colleagues' study4Wan EYF Chui CSL Lai FTT et al.Bell's palsy following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines: a case series and nested case-control study.Lancet Infect Dis. 2021; (published online Aug 16.)https://doi.org/10.1016/S1473-3099(21)00451-5Summary Full Text Full Text PDF PubMed Google Scholar in The Lancet Infectious Diseases showed an overall increased risk of Bell's palsy after immunisation with CoronaVac (Sinovac Biotech), a vaccine that uses the inactivated virus. Despite the numerical imbalance of Bell's palsy cases observed in trials of the two mRNA vaccines,5Polack FP Thomas SJ Kitchin N et al.Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine.N Engl J Med. 2020; 383: 2603-2615Crossref PubMed Scopus (8385) Google Scholar, 6Baden LR El Sahly HM Essink B et al.Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine.N Engl J Med. 2021; 384: 403-416Crossref PubMed Scopus (5699) Google Scholar but not in those of other vaccine platforms,7Voysey M Clemens SAC Madhi SA et al.Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.Lancet. 2021; 397: 99-111Summary Full Text Full Text PDF PubMed Scopus (2973) Google Scholar the relevant regulatory bodies, including the US Food and Drug Administration and the UK Medicines and Healthcare products Regulatory Agency among others, have argued that the observed frequency in vaccinated individuals was no higher than the expected background rate. A closer look at these figures and analysis of crude real-world data from pharmacovigilance agencies estimated that Bell's palsy occurred more often in the mRNA vaccine groups than would be expected in the general population.8Cirillo N Doan R Bell's palsy and SARS-CoV-2 vaccines—an unfolding story.Lancet Infect Dis. 2021; (published online June 7.)https://doi.org/10.1016/S1473-3099(21)00273-5Summary Full Text Full Text PDF PubMed Google Scholar Two research letters later provided indirect evidence for the safety of mRNA vaccines from a Bell's palsy standpoint. In one letter, the WHO pharmacovigilance database was used to show that mRNA COVID-19 vaccines did not confer an increased risk of facial paralysis when compared with other viral vaccines.9Renoud L Khouri C Revol B et al.Association of facial paralysis with mRNA COVID-19 vaccines: a disproportionality analysis using the World Health Organization pharmacovigilance database.JAMA Intern Med. 2021; (published online April 27.)https://doi.org/10.1001/jamainternmed.2021.2219Crossref PubMed Scopus (69) Google Scholar In the other letter, the authors concluded that patients with COVID-19 have a greater risk of acquiring Bell's palsy than those who were vaccinated against the disease.10Tamaki A Cabrera CI Li S et al.Incidence of Bell palsy in patients with COVID-19.JAMA Otolaryngol Head Neck Surg. 2021; (published online June 24.)https://doi.org/10.1001/jamaoto.2021.1266Crossref PubMed Scopus (45) Google Scholar The controversy was again addressed by the findings from a relatively small case-control study from Israel,11Shemer A Pras E Einan-Lifshitz A Dubinsky-Pertzov B Hecht I Association of COVID-19 vaccination and facial nerve palsy: a case-control study.JAMA Otolaryngol Head Neck Surg. 2021; (published online June 24.)https://doi.org/10.1001/jamaoto.2021.1259Crossref PubMed Scopus (75) Google Scholar in which 37 patients with Bell's palsy were matched to 74 controls and no association with mRNA-based SARS-CoV-2 vaccination was found (adjusted odds ratio [OR] for exposure 0·84 [95% CI 0·37–1·90; p=0·67]). Of note, hospital admissions due to facial nerve palsy in January and February, 2020, and January and February, 2021, were 29–112% greater than in the same period in the 5 preceding years, but this was not deemed significant.11Shemer A Pras E Einan-Lifshitz A Dubinsky-Pertzov B Hecht I Association of COVID-19 vaccination and facial nerve palsy: a case-control study.JAMA Otolaryngol Head Neck Surg. 2021; (published online June 24.)https://doi.org/10.1001/jamaoto.2021.1259Crossref PubMed Scopus (75) Google Scholar Wan and colleagues used different population-based approaches to evaluate the possible association between Bell's palsy and mRNA (BNT162b2; Fosun–BioNTech) and inactivated virus (CoronaVac) vaccines in Hong Kong.4Wan EYF Chui CSL Lai FTT et al.Bell's palsy following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines: a case series and nested case-control study.Lancet Infect Dis. 2021; (published online Aug 16.)https://doi.org/10.1016/S1473-3099(21)00451-5Summary Full Text Full Text PDF PubMed Google Scholar Using a voluntary surveillance reporting system and electronic health records, the authors found a substantial increase in the age-standardised incidence of Bell's palsy during the vaccination programme compared with the same period in previous years. For example, after accounting for confounding variables, the incidence difference with the same observation period in 2020 was 41·5 cases per 100 000 person-years (95% CI 11·7 to 71·4) for CoronaVac and 17·0 (−6·6 to 40·6) for BNT162b2. In the nested case-control study, 298 patients with clinically confirmed Bell's palsy were selected. 1181 control individuals were randomly matched (4:1) to each case according to sex, age, date of hospital attendance (to control for seasonality of the disease), and setting (to reduce selection bias). The results suggested a significantly increased risk of Bell's palsy associated with receiving CoronaVac (adjusted OR 2·385 [95% CI 1·415–4·022]; p=0·0011) for CoronaVac, but no significant difference in risk associated with receiving BNT162b2 (1·755 [0·886–3·77]; p=0·11). Owing to the timing of vaccine rollout in Hong Kong, vaccination was notably less common in this population compared with in the study done in Israel. For example, in Wan and colleagues' study, only 84 (7·1%) individuals in the control population had been vaccinated,4Wan EYF Chui CSL Lai FTT et al.Bell's palsy following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines: a case series and nested case-control study.Lancet Infect Dis. 2021; (published online Aug 16.)https://doi.org/10.1016/S1473-3099(21)00451-5Summary Full Text Full Text PDF PubMed Google Scholar compared with 59·5% in the previous study,11Shemer A Pras E Einan-Lifshitz A Dubinsky-Pertzov B Hecht I Association of COVID-19 vaccination and facial nerve palsy: a case-control study.JAMA Otolaryngol Head Neck Surg. 2021; (published online June 24.)https://doi.org/10.1001/jamaoto.2021.1259Crossref PubMed Scopus (75) Google Scholar which might have influenced the strength of the association. On the other hand, data collected during the early stages of vaccination in Hong Kong might have introduced selection bias because only people in specific categories of workers and age groups were vaccinated. These caveats are not trivial because the background incidence of Bell's palsy varies greatly with age12Li X Ostropolets A Makadia R et al.Characterising the background incidence rates of adverse events of special interest for COVID-19 vaccines in eight countries: multinational network cohort study.BMJ. 2021; 373n1435Google Scholar and the vaccines are likely to have different safety profiles in different age groups. From a clinical, patient-oriented perspective, none of the studies published so far provide definitive evidence to inform the choice of a specific vaccine in individuals worldwide with a history of Bell's palsy. However, the data published by Wan and colleagues do offer valuable information for a rational and informed choice of COVID-19 vaccines for patients in Hong Kong, and for those in countries where both BNT162b2 and CoronaVac are available. While waiting for conclusive evidence on vaccine-associated facial paralysis, one certainty remains: the benefit of getting vaccinated outweighs any possible risk. We declare no competing interests. Bell's palsy following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines: a case series and nested case-control studyOur findings suggest an overall increased risk of Bell's palsy after CoronaVac vaccination. However, the beneficial and protective effects of the inactivated COVID-19 vaccine far outweigh the risk of this generally self-limiting adverse event. Additional studies are needed in other regions to confirm our findings. Full-Text PDF" @default.
• W4225751411 created "2022-05-05" @default.
• W4225751411 creator A5056401353 @default.
• W4225751411 creator A5062723643 @default.
• W4225751411 date "2022-01-01" @default.
• W4225751411 modified "2023-10-18" @default.
• W4225751411 title "The association between COVID-19 vaccination and Bell's palsy" @default.
• W4225751411 cites W3111255098 @default.
• W4225751411 cites W3111590711 @default.
• W4225751411 cites W3128509290 @default.
• W4225751411 cites W3159001141 @default.
• W4225751411 cites W3160918102 @default.
• W4225751411 cites W3166109011 @default.
• W4225751411 cites W3169089823 @default.
• W4225751411 cites W3173785882 @default.
• W4225751411 cites W3176748722 @default.
• W4225751411 cites W3193761537 @default.
• W4225751411 cites W4205483821 @default.
• W4225751411 doi "https://doi.org/10.1016/s1473-3099(21)00467-9" @default.
• W4225751411 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34411533" @default.
• W4225751411 hasPublicationYear "2022" @default.
• W4225751411 type Work @default.
• W4225751411 citedByCount "22" @default.
• W4225751411 countsByYear W42257514112021 @default.
• W4225751411 countsByYear W42257514112022 @default.
• W4225751411 countsByYear W42257514112023 @default.
• W4225751411 crossrefType "journal-article" @default.
• W4225751411 hasAuthorship W4225751411A5056401353 @default.
• W4225751411 hasAuthorship W4225751411A5062723643 @default.
• W4225751411 hasBestOaLocation W42257514111 @default.
• W4225751411 hasConcept C116675565 @default.
• W4225751411 hasConcept C126322002 @default.
• W4225751411 hasConcept C142724271 @default.
• W4225751411 hasConcept C142853389 @default.
• W4225751411 hasConcept C15744967 @default.
• W4225751411 hasConcept C159047783 @default.
• W4225751411 hasConcept C204787440 @default.
• W4225751411 hasConcept C22070199 @default.
• W4225751411 hasConcept C2776775940 @default.
• W4225751411 hasConcept C2778097013 @default.
• W4225751411 hasConcept C2779134260 @default.
• W4225751411 hasConcept C3006700255 @default.
• W4225751411 hasConcept C3007834351 @default.
• W4225751411 hasConcept C3008058167 @default.
• W4225751411 hasConcept C524204448 @default.
• W4225751411 hasConcept C542102704 @default.
• W4225751411 hasConcept C71924100 @default.
• W4225751411 hasConceptScore W4225751411C116675565 @default.
• W4225751411 hasConceptScore W4225751411C126322002 @default.
• W4225751411 hasConceptScore W4225751411C142724271 @default.
• W4225751411 hasConceptScore W4225751411C142853389 @default.
• W4225751411 hasConceptScore W4225751411C15744967 @default.
• W4225751411 hasConceptScore W4225751411C159047783 @default.
• W4225751411 hasConceptScore W4225751411C204787440 @default.
• W4225751411 hasConceptScore W4225751411C22070199 @default.
• W4225751411 hasConceptScore W4225751411C2776775940 @default.
• W4225751411 hasConceptScore W4225751411C2778097013 @default.
• W4225751411 hasConceptScore W4225751411C2779134260 @default.
• W4225751411 hasConceptScore W4225751411C3006700255 @default.
• W4225751411 hasConceptScore W4225751411C3007834351 @default.
• W4225751411 hasConceptScore W4225751411C3008058167 @default.
• W4225751411 hasConceptScore W4225751411C524204448 @default.
• W4225751411 hasConceptScore W4225751411C542102704 @default.
• W4225751411 hasConceptScore W4225751411C71924100 @default.
• W4225751411 hasIssue "1" @default.
• W4225751411 hasLocation W42257514111 @default.
• W4225751411 hasLocation W42257514112 @default.
• W4225751411 hasLocation W42257514113 @default.
• W4225751411 hasOpenAccess W4225751411 @default.
• W4225751411 hasPrimaryLocation W42257514111 @default.
• W4225751411 hasRelatedWork W3009669391 @default.
• W4225751411 hasRelatedWork W3036314732 @default.
• W4225751411 hasRelatedWork W3127693599 @default.
• W4225751411 hasRelatedWork W3198183218 @default.
• W4225751411 hasRelatedWork W4200329650 @default.
• W4225751411 hasRelatedWork W4205317059 @default.
• W4225751411 hasRelatedWork W4206669628 @default.
• W4225751411 hasRelatedWork W4210401150 @default.
• W4225751411 hasRelatedWork W4382894326 @default.
• W4225751411 hasRelatedWork W3127156785 @default.
• W4225751411 hasVolume "22" @default.
• W4225751411 isParatext "false" @default.
• W4225751411 isRetracted "false" @default.
• W4225751411 workType "article" @default.